When was Huntington Study Group founded?

Huntington Study Group was founded in 1993.

Where is Huntington Study Group located?

Huntington Study Group is headquartered in Rochester, United States.

How many employees does Huntington Study Group have?

As of Apr 30, 2026, the latest employee count at Huntington Study Group is 22.

Is Huntington Study Group a funded company?

Huntington Study Group is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Huntington Study Group rank among its competitors?

Huntington Study Group ranks 74th amongst 1058 active competitors, of which 65 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Ipsen, which secured $618K in Dec, 2023.

Who are the top competitors of Huntington Study Group?

Huntington Study Group's top competitors include WuXi AppTec, ANI Pharmaceuticals and EVERSANA. Among them, Ipsen secured the most recent funding round in December, 2023.

Huntington Study Group - 2026 Company Profile & Competitors

Huntington Study Group's employee count trend

Huntington Study Group has 22 employees as of Apr 26. Here is Huntington Study Group's employee count trend over the years:

Employee count trend for Huntington Study Group

Uncover Huntington Study Group's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Huntington Study Group include WuXi AppTec, ANI Pharmaceuticals and EVERSANA. Here is the list of Top 10 competitors of Huntington Study Group, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	79/100
2nd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	Ampersand Capital, US Bank & 4 others	64/100
3rd	EVERSANA 2014, Milwaukee (United States), Funding Raised	Provider of consulting services for drug pricing access, reimbursement, and regulatory support	-	ACE & Company, North Sky Capital & 2 others	63/100
4th	Aptar 1992, Crystal Lake (United States), Public	Provider of regulatory support, brand differentiation, and prototyping services	-	Al Zayani Investments	63/100
5th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, PAI Partners & 2 others	62/100
6th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	61/100
7th	Zuellig Pharma 1992, Singapore (Singapore), Funding Raised	Provider of clinical research, quality management, logistics, and clinical trial supply services	-	Temasek	61/100
8th	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Blackstone & 7 others	60/100
9th	China Medical System 1992, Shenzhen (China), Public	Manufacturer of generic formulations	-	CMS Ventures	55/100
10th	Avania 1988, Brunswick (Australia), Acquired	Provider of regulatory, clinical trials and analytic services	-	Kester Capital, Omnes Capital & 1 others	55/100
74th	Huntington Study Group 1993, Rochester (United States), Unfunded	Provider of disease clinical trials, advisory, and other services	-	-	38/100